1. Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination
- Author
-
Trkola, A, Mahan, AE, Jennewein, MF, Suscovich, T, Dionne, K, Tedesco, J, Chung, AW, Streeck, H, Pau, M, Schuitemaker, H, Francis, D, Fast, P, Laufer, D, Walker, BD, Baden, L, Barouch, DH, Alter, G, Trkola, A, Mahan, AE, Jennewein, MF, Suscovich, T, Dionne, K, Tedesco, J, Chung, AW, Streeck, H, Pau, M, Schuitemaker, H, Francis, D, Fast, P, Laufer, D, Walker, BD, Baden, L, Barouch, DH, and Alter, G
- Abstract
Antibody effector functions, such as antibody-dependent cellular cytotoxicity, complement deposition, and antibody-dependent phagocytosis, play a critical role in immunity against multiple pathogens, particularly in the absence of neutralizing activity. Two modifications to the IgG constant domain (Fc domain) regulate antibody functionality: changes in antibody subclass and changes in a single N-linked glycan located in the CH2 domain of the IgG Fc. Together, these modifications provide a specific set of instructions to the innate immune system to direct the elimination of antibody-bound antigens. While it is clear that subclass selection is actively regulated during the course of natural infection, it is unclear whether antibody glycosylation can be tuned, in a signal-specific or pathogen-specific manner. Here, we show that antibody glycosylation is determined in an antigen- and pathogen-specific manner during HIV infection. Moreover, while dramatic differences exist in bulk IgG glycosylation among individuals in distinct geographical locations, immunization is able to overcome these differences and elicit antigen-specific antibodies with similar antibody glycosylation patterns. Additionally, distinct vaccine regimens induced different antigen-specific IgG glycosylation profiles, suggesting that antibody glycosylation is not only programmable but can be manipulated via the delivery of distinct inflammatory signals during B cell priming. These data strongly suggest that the immune system naturally drives antibody glycosylation in an antigen-specific manner and highlights a promising means by which next-generation therapeutics and vaccines can harness the antiviral activity of the innate immune system via directed alterations in antibody glycosylation in vivo. .
- Published
- 2016